Innate Pharma, S.a.

University of Genova

Innate Pharma S.a.s.

Innate Pharma

Universita Di Genova

Novo Nordisk A/s

University of Genoa

Novo Nordisk-a/s Novo Alle

Institut National De La Sante Et De La Recherche Medicale

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Dimes - Dipartimento Do Medicina Sperimentale - Universita Degli Studi Di Genova

Universita Degli Studi Di Genova, Dipartimento Di Medicina Sperimentale

Dimes-dipartimento Do Medicina Sperimentale

Alessandro Moretta

Pascale Andre

Mariella Della Chiesa

Roberto Biassoni

Laurent Gauthier

Francois Romagne

Cristina Bottino

Peter Andreas Nicolai Reumert Wagtmann

Lorenzo Moretta

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Ivan Svendsen

Benjamin Rossi

Yannis Morel

Soren Berg Padkjaer

Silvia Parolini

Christina Bottino

Roberta Castriconi

Michael Wilken

Matthias Thorolfsson

Emanuela Marcenaro

Nicolas Anfossi

Peter Andreas Wagtmann

Mathieu Blery

Ido Bachelet

Petrus Johannes Louis Spee

Søren Berg Padkær

Eric Vivier

Pieter Spee

François Romagne

Ariel Munitz

Francesca Levi-Schaffer

Soeren Berg Padkaer

Francois Romagné

Maria Cristina Mingari

Elena Tomasello

Frédéric Vely

Lucia Olcese

Pieter Johannes Louis Spee

Matthias Thórólfsson

Milchael Wilken

Petrus Johannes Loius Spee

Laurant Gauthier

Søren Berg Padkjær

Soren Berg Padkaer

Ulrik Morch

Soeren Berg Padkjaer

Roberta University Of Genova Castriconi

Lorenzo Istituto Giannina Gaslini Moretta

Søren Berg Padkaer

The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

Compositions and methods for regulating NK cell activity

The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

Monoclonal antibodies against NKG2A

The present invention relates to novel antibody compositions for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy

The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and S&#xe9;zary Syndrome.

Anti-KIR3D antibodies

The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.

Compositions and methods for treating proliferative disorders

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.

Nucleic acids encoding human anti-kir antibodies

The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.

Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor

Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and/or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, Fc&#x3b5;RI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described.

Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

The invention concerns novel means for diagnosing, preventing, compensating, treating an abnormal or unwanted functioning of KAR receptors (Killer cell Activatory Receptor), counterparts of non-inhibiting KIR receptors (Keller cell Inhibitory Receptors) of the immunoglobulin or lectin type. The invention concerns in particular, novel KARAP (KAR-Associated Proteins) polypeptides and their biological applications. A KARAP polypeptide is naturally associated with a KAR receptor, and in the absence of such a KARAP, said KAR receptor is naturally incapable of transducing an activating signal that can be detected. The application also concerns methods for obtaining or identifying such KARAP polypeptides.

Polypeptides associated with activatory receptors and their biological applications

Growing community of inventors

Genoa, Italy

Alessandro Moretta